130
Participants
Start Date
December 1, 2022
Primary Completion Date
February 15, 2027
Study Completion Date
August 15, 2028
Teclistamab (Tec)
Subcutaneous administration of Teclistamab
Daratumumab
Subcutaneous administration of Daratumumab
Dexamethasone
administered i.v. or orally
Lenalidomide
Administration oral
Bortezomib
Subcutaneous administration
Talquetamab
Subcutaneous administration of Daratumumab
RECRUITING
Charité University Medicin Berlin, Berlin
RECRUITING
Hamburg University Clinic Eppendorf, Hamburg
RECRUITING
Asklepios Clinic Hamburg Altona, Hamburg
RECRUITING
University Clinic Schleswig-Holstein Campus Kiel, Kiel
RECRUITING
University Clinic Düsseldorf, Düsseldorf
RECRUITING
University Hospital Heidelberg, Heidelberg
RECRUITING
University Clinic Freiburg, Freiburg im Breisgau
RECRUITING
Technical University Munich, Munich
RECRUITING
Clinic Chemnitz gGmbH, Chemnitz
RECRUITING
University Clinic Technical University Dresden, Dresden
RECRUITING
University Würzburg, Würzburg
Janssen Research & Development, LLC
INDUSTRY
Deutsche Studiengruppe Multiples Myelom (DSMM)
UNKNOWN
University of Heidelberg Medical Center
OTHER